New developments in the management of urinary incontinence

Minerva Ginecologica

Volumn 57, Issue 5, 2005, Pages 485-500

  Vella, M ^a,b   Cardozo, L ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b Urogynaecology Research Registrar   (United Kingdom)

Author keywords

Anticholinergics; Bladder; Duloxetine; Urinary incontinence, diagnosis; Urinary incontinence, therapy

Indexed keywords

BOTULINUM TOXIN A; CAPSAICIN; CAPSAICIN DERIVATIVE; DESMOPRESSIN; DULOXETINE; ESTROGEN; IMIPRAMINE; OXYBUTYNIN; PLACEBO; PROPIVERINE; RESINIFERATOXIN; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

BLADDER INJURY; BLADDER RECONSTRUCTION; CLINICAL TRIAL; COLPOSUSPENSION; CONSERVATIVE TREATMENT; CONSTIPATION; CORRELATION ANALYSIS; CYSTOMETRY; DENERVATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; ELECTROSTIMULATION; FATIGUE; FEEDBACK SYSTEM; FLUID INTAKE; HUMAN; INSOMNIA; INTERMETHOD COMPARISON; LAPAROSCOPIC SURGERY; LIFESTYLE; META ANALYSIS; MICTURITION; MINIMALLY INVASIVE SURGERY; MUSCLE EXERCISE; NAUSEA; OPERATION DURATION; OVERACTIVE BLADDER; PHYSIOTHERAPY; POSTOPERATIVE COMPLICATION; PRURITUS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STRESS INCONTINENCE; SURGICAL RISK; SURGICAL TECHNIQUE; SUSTAINED RELEASE PREPARATION; SYSTEMATIC REVIEW; TENSION FREE VAGINAL TAPE; TRANSOBTURATOR SUBURETHRAL TAPE; TREATMENT INDICATION; TREATMENT OUTCOME; URINE INCONTINENCE; URODYNAMICS; UROFLOWMETRY; UROLITHIASIS; XEROSTOMIA;

FEMALE; HUMANS; URINARY INCONTINENCE; URODYNAMICS;

EID: 27844590709     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al. The standardisation of terminology of lower urinary tract function. Report from the standardisation committee of the International Continence society. Neurol Urodynam 2002;21:167-78.
2. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997;104:1374-9.
3. Hannested YS, Rortveit G, Sandvik H, Hunsakar S; Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. A community-based epidemiological survey of female urinary incontinence, the Norwegian EPINCONT Study. Epidemiology of Incontinence in the County of Nord-Trondelag. J Clin Epidemiol 2000;53:1150-7.
4. Hu TW, Wager TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004;63:461-5.
5. Abrams P, Blaivas JG, Stanton S, Andersen JT. The Standardisation of terminology of lower urinary tract function. Neurourol Urodynam 1988;7:403-26.
6. Spence-Jones C, Kamm MA, Henry MM, Hudson CN. Bowel dysfunction: a pathogenic factor in utero-vaginal prolapse and urinary stress incontinence. Br J Obstet Gynaecol 1994;101:147-52.
7. Resnick NM, Yalla SV. Current concepts: management of urinary incontinence in the elderly. N Engl J Med 1985;313:800-15.
8. Jarvis GJ, Hall S, Stamp S, Millar DR. An assessment of urodynamic investigation in incontinent women. Br J Obstet Gynaecol 1980;87:873-96.
9. James M, Jackson S, Shepherd A, Abrams P. Pure stress leakage symptomatology: is it safe to discount detrusor instability? Br J Obstet Gynaecol 1999;106:1255-8.
10. Van Waalwijk van Doom ES, Zwiers W, Wetzels LL, Debruyne FM. A comparitive study between standard and ambulant urodynamics. Neurourol Urodyn 1987;6:156.
11. Kelleher C. Epidemiology and classification of Incontinence. In: Cardozo LD editor. Urogynaecology. New York, NY: Churchill Livingstone; 1997. p. 3-23.
12. Abrams P, Fenely R, Torrens M. Patient Assessment. In: Abrams P, Fenely R, Torrens M editors. Urodynamics. 1st ed. New York: Springer; 1983. p. 6-27.
13. Larsson G, Victor A. Micturition patterns in a healthy female population, studied with a frequency-volume chart. Scand J Urol Nephrol Suppl 1988;114:53-7.
14. McCormack M, Infante-Rivard C, Schick E. Agreement between clinical methods of measurment of urinary frequency and functional bladder capacity. Br J Urol 1992;9:17-21.
15. Linjakumpu T, Hartikainen S, Klaukka T, Koponen H, Kivela SL, Isoaho R. Psychotropics among the home dwelling elderly -increasing trends. Int J Geriatr Psychiatry 2002;17:874-83.
16. Morkved S, Bo K, Fjortoft T. Effect of adding biofeedback to pelvic floor muscle training to treat urodynamic stress incontinence. Obstet Gynecol 2002;100: 730-9.
17. Finckenhagen HB, Bo K. The effect of pelvic floor exercise on stress urinary incontinence. Tidsskr Nor Laegeforen 1998;118:2015-7.
18. Hay-Smith EJ, Bo Berghman's LC, Hendricks HJ, de Bie Ra, van Waalwijk van Doorn ES. Pelvic floor muscle training for urinary incontinence in women. Cochrane Database Syst Rev 2001;(1):CD001407.
19. Miller JM, Perucchini D, Carchidi LT, DeLancey JO, Ashton-Miller J. Pelvic floor muscle contraction during a cough and decreased vesical neck mobility. Obstet Gynecol 2001;97:255-60.
20. Miller JM, Ashton-Miller JA, DeLancey JO. A pelvic muscle precontraction can reduce cough related urine loss in selected women with mild SUI. J Am Geriatr Soc 1998;46:870-4.
21. Bo K, Talseth T, Holme I. Single blind, randomised controlled trial of pelvic floor exercises, electrical stimulation, vaginal cones, and no treatment in management of genuine stress incontinence in women. BMJ 1999; 318:487-93.
22. Glazener CM, Herbison GP, Wilson PD, Mac Arthur C, Lang GD, Gee H et al. Conservative management of persistent postnatal urinary and faecal incontinence: randomised controlled trial. BMJ 2001;323:593-6.
23. Morkved S, Bo K. Effect of postpartum pelvic floor muscle training in prevention and treatment of urinary incontinence: a one-year follow-up. BJOG 2000;107: 1022-8.
24. Wilson P, Herbison P, Glazener C et al. Obstetric practice and urinary incontinence 5-7 years after delivery. Neurourol Urodynam 2002;21:284-300.
25. Jeffcoate TN, Francis WJ. Urgency incontinence in the female. Am J Obstet Gynecol 1966;94:604-18.
26. Berghams LC, Hendriks HJ, De Bie RA, van Waalwijk van Doorn ES, Bo K, van Kerrebroeck PE. Conservative treatment of urge urinary incontinence in women: a systematic review of randomised clinical trials. BJU Int 2000;85:254-63.
27. Thor KB, Katofiasc MA. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the cloralose-anaesthetised female cat. J Pharmacol Exp Ther 1995;274:1014-24.
28. Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynaecol 2002;187:40-8.
29. Millard R, Moore K, Yalcin I, Bump R. Duloxetine vs placebo in the treatment of stress urinary incontinence: a global phase 3 study. Neurol Urodynam 2003;22: 482-3.
30. Cardozo L, Drutz H, Baygani S, Bump R. Pharmaco-logical treatment of women awaiting surgery for stress incontinence. Obstet Gynecol 2004;104:511-9.
31. Duloxetine Summary of product characteristics. Eli Lilly and company, p. 5
32. Thuroff JW, Bunke B, Ebner A, Faber P, de Geeter P, Hannappel J et al. Randomized double-blind multicentre trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 1991;145:813-6, discussion 816-7.
33. Anderrson KE, Appell R, Awad S, Chapple C, Drutz H, Finkbeiner A et al. Pharmacologic treatment of urinary incontinence. In: Abrams P, Cardozo LD, Khoury S, Wein A editors. Incontinence: 2nd edition International Consultation on Incontinence. Plymouth, UK: Plymbridge Distributors Ltd; 2002. p. 479-511.
34. Stahl MMS, Ekstrom B, Sparf B, Mattiasson A, Andersson KE. Urodynamic and other effects of Tolteridone: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 1995;14:647-55.
35. Brynne N, Stahl MMS, Hallen B, Edlund PO, Palmer L, Hoglund P et al. Pharmacokinetics and pharmacodynamics of tolteridone in man: a new drug in the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997;35:287-95.
36. Brynne N, Dalen P, Alvan G, Bertilsson L, Gabrielsson J. Influence of CYP2D6 polymorphism on the pharmcokinetics and pharmacodynamics of tolteridone. Clin Pharmacol Ther 1998;63:529-39.
37. Abrams P, Freeman R, Anderstom C, Mattiasson A. Tolteridone, a new anti-muscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801-10.
38. Van Kerrebroek P, Kreder K, Jonas U, Zimmer N, Wein A; Tolteridone Study Group. Tolteridone once daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57:414-21.
39. Dmochowski RR, Davila GW, Zinner NR, Gittelman MC, Saltzstein DR, Lyttle S et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002;168:580-6.
40. Gleason DM, Susset J, White C, Munoz DR, Sand PK. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Ditrapan XL Study Group. Urology 1999;54:420-3.
41. Cardozo L, Kuzmin I, Lisek MI and European YM905 Study Group. Solifenacin in symptomatic Overactive Bladder. YM905 Results of a Phase 3, Randomised, Placebo-controlled Trial.
42. Chapple CR, Rechberger T, Al-Shukri, Meffan P, Everaert K, Huang M et al. Randomised double-blind placebo and tolteridone-controlled trial of the once-daily antimuscarinic agent solefanicin in patient with symptomatic overactive bladder. BJU Int 2004;93: 303-10.
43. Schladitz Keil G, Spanh H, Mutschler E. Determination of bioavailability of the quaternary ammonium compound trospium chloride in man for the urinary excretion data. Arzneimittelforschung 1986;36:984-7.
44. Cardozo LD, Chapple CR, Toozs-Hobson P, Grosse-Freese M, Bulitta M, Lehmacher W et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo- controlled, randomized, double-blind multi-centre clnical trial. BJU Int 2000;85:659-64.
45. Madersbaher H, Stoher M, Richter R, Burgdorfer H., Hachen HJ, Murtz G. Trospium chloride versus oxybutynin: a randomized, double-blind multicentre trial in the treatment of detrusor hyperreflexia. Br J Urol 1995;75:452-6.
46. Haruno A, Yamasaki Y, Miyoshi K, Miyake H, Tsuchiya K, Kosaka M et al. [Effects of propiverine hydrochloride and its metabolites on isolated guinea pig urinary bladder] Nippon Yakurigaku Zasshi 1989;94:145-50. Japanese.
47. Mazur D, Whnert J, Dorshner W, Schubert G, Herfurth G, Alken RG. Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. Scan J. Urol Nephrol 1995;29: 289-94.
48. Stoher M, Madersbacher H, Richter R, Wehnert J, Dreikorn K. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyper-reflexia: a double-blind, placebo-controlled clinical trial. Spinal Cord 1999;37:196-200.
49. Baldessarini KJ. Drugs in the treatment of psychiatric disorders. In: Goodman and Gilman Pharmacological Basis of Therapeutics. 7th ed. New York: McMillan Publishing Co; 1985. p. 387-445.
50. Castelden CM, Duffin HM, Gulati RS. Double-blind study of imipramine and placebo for incontinence due to bladder instability. Age Ageing 1986;15:229-303.
51. Diokono AC, Hyndman CW, Hardy DA, Lpides J. Comparison of action of imipramine (tofranil) and propantheline (Probanthine) on detrusor contraction. J Urol 1972;107:42-3.
52. Hilton P, Hertogs K, Stanton SL. The use of Demopressin (DDVAP) for nocturia in women multiple sclerosis. J Neurol Neurosurg Psychiatry 1983;46:854-5.
53. Robinson D, Cardozo L, Akeson M et al. Women take control; desmopressin - a drug for daytime urinary incontinence. Neurourol Urodyn 2002;21:385-6.
54. de Seze M, Wiart L, Joseph PA, Dosque JP, Mazaux JM, Barat M. Caspaicin and neurogenic detrusor hyper-reflexia: a doubleblind placebo-controlled study in 20 patients with spinal cord lesions. Neurourol Urodyn 1998;17:513-23.
55. Salmon UL, Walter RI, Gast SH. The use of oestrogen in the treatment of dysuria and incontinence in post-menopausal women. Am J Obstet Gynecol 1941;14: 23-31.
56. Youngblood VH, Tomlin EM, Davis JB. Senile urethritis in women. J Urol 1957;78:150-2.
57. Fantl JA, Cardozo LD, McClish DK and the Hormones and Urogenital Therapy Committee. Oestrogen therapy in the management of of incontinence in post-menopausal women: a meta-analysis. First report of the Hormones and Urogenital therapy Committee. Obstet Gynaecol 1994;83:12-8.
58. Lazzeri M, Beneforti P, Turini D. Urodynamic effects of intra-vesical resiniferatoxin in humans: preliminary results in stable and unstable detrusor. J Urol 1997;158: 2093-7.
59. Bombier L, Freeman RM, Perkins EP, Williams M, Shaw SR. Why do women have voiding dysfunction and de novo detrusor instability after colposuspension? BJOG 2002;109:402-12.
60. Black NA, Downs SH. The effectiveness of surgery for stress incontinence in women: a systematic review. Br J Urol 1996;78:497-510.
61. Moehre B, Carey M, Wilson D. Laparoscopic colposuspension: a systemtic review. BJOG 2003;110:230-5.
62. Ward K, Hilton P; United kingdom and Ireland Tension-free Vaginal Tape Trial Group. Prospective multicentre randomised trial of tension-free vaginal tape and colposuspension as primary treatment for stress incontinence. BMJ 2002;325:67.
63. de Tayrac R, Deffieux X, Droupy S, Chveaud-Lambling A, Calvanese-Benamour L, Fernandez H. A prospective randomized trial comparing tension-free vaginal tape and trabsobturator suburethral tape for surgical treatment of stress urinary incontinence. Am J Obstet Gyncol 2004;190:602-8.
64. Deval B, Levardon M, Samain E, Rafii A, Cortesse A, Amarenco G et al. A French multicentre clinical trial of SPARC for stress urinary incontinence. Eur Urol 2003;44:254-8, discussion 258-9.
65. Dietz HP, Foote AJ, Mak HL, Wilson PD. TVT and SPARC suburethral slings: a case-control series. Int Urogynaecol J 2004;15:129-31.
66. Lee PE, Rung RC, Drutz HP. Periurethral autologous fat injection as treatment for female stress incontinence: a randomized, double-blind controlled trial. J Urol 2001; 165:153-8.
67. Lightner D, Calvosa C, Andersen R, Klimberg I, Brito CG, Snyder J et al. A new injectable bulking agen for treatment of stress urinary incontinence: results of a multicentre, randomised, controlled, double-blind study of Durasphere. Urology 2001;58:12-5.
68. Anders K, Khullar V, Cardozo L, Bidmead J, Athanasiou S, Hobson P et al. Gax collagen or macroplastique does it make a difference? Int Urogyanecol J Pelvic Floor Dysfunct 1999;1010 Suppl 1:S46.
69. Chapple C, Sultan AH, Cervigni M. Efficacy and safety of the Zuidex system for the treatment of stress urinary incontinence:6-month results of an open, multicentre study. Proceedings of the 34th Annual Scientific Meeting of the International Continence Society, 2004, 25 August, Paris, France.
70. Macroplastique Implants Technical Overview. Maastricht, The Netherlands: Uroplasty BV;1995
71. Phelan MW, Franks M, Somogyi GT, Yokoyama T, Fraser MO, Lavelle JP et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiing dysfunction. J Urol 200;165: 1107-10.
72. Gallien P, Robineau S, Verin M, Le Bot MP, Nicolas B, Brissot R, Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin. Arch Phys Med Rehabil 1998;79:715-7.
73. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detrusor- sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 1996;155:1023-9.
74. Schmidt RA, Jonas U, Oleson KA, Janknegt RA, Hassouna MM, Siegel SW et al. Sacral nerve stimulation for treatment of refractory urinary re incontinence. Sacral Nerve Stimulation Study Group. J Urol 1999;162: 352-7.
75. Mark SD, McRae CU, Arnold EP, Gowland SP. Clam cystoplasty for the overactive bladder: a review of 23 cases. Aust NZ J Surg 1994;64:88-90.
76. Westney OL, McGuire EJ. Surgical procedures for the treatment of urge incontinence. Tech Urol 2001;7: 126-32.
77. Avron J, Monane M, Gurnitz JH, Glynn RJ, Choodnovsky I, Lipsitz LA. Reduction of bacturia and pyuria after ingestion of cranberry juice. JAMA 1994;271: 751-4.
78. Gough DCS. Enterocystoplasty. BJU Int 2001;88:739-43.
79. Fernandez-Arjona M, Herrerro L, Romero J, Nieto S, Martin R, Pereira I. Synchronous signet ring cell carcinoma and squamous cell carcinoma arising in an augmented ileocystoplasty. Case report and review of the literature. Eur Urol 1996;29:125-8.